Literature DB >> 9377962

Distinctive clinical features of portopulmonary hypertension.

P C Kuo1, J S Plotkin, L B Johnson, C D Howell, J M Laurin, S T Bartlett, L J Rubin.   

Abstract

STUDY
OBJECTIVE: To differentiate the cardiopulmonary profile of portopulmonary hypertension (PPHTN) from that of primary pulmonary hypertension and chronic liver disease.
DESIGN: Retrospective survey.
SETTING: Tertiary care center. PATIENTS: Thirty patients with cardiac catheterization-proven PPHTN were compared to 30 randomly selected patients with primary pulmonary hypertension alone and 30 patients with chronic liver disease alone necessitating consideration of liver transplantation (L-CONT).
INTERVENTIONS: All patients underwent right heart catheterization, echocardiography, ECG, chest radiography, pulmonary function tests, ventilation-perfusion scanning, and room air arterial blood gas measurements.
RESULTS: Patients with PPHTN exhibited elevated pulmonary pressures (mean pulmonary pressure, 48.6+/-2.1 mm Hg) and pulmonary vascular resistance (11.6+/-1.6 mm Hg/L/min/m2) with simultaneous elevation in the cardiac index (3.8+/-0.3 L/min/m2) and depression of systemic vascular resistance (24.9+/-1.7 mm Hg/L/min/m2). Arterial blood gas measurements indicate that PPHTN exhibits a significant accentuation of the chronic respiratory alkalosis (PCO2, 28.7+/-0.5 mm Hg) usually seen with chronic liver disease and pulmonary hypertension. In addition, patients with PPHTN have an increased alveolar-arterial gradient (27.0+/-2.7 mm Hg) when compared to patients with L-CONT, suggesting impaired gas exchange.
CONCLUSIONS: PPHTN is associated with a unique clinical profile that possesses characteristics common to and exclusive of liver disease and primary pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9377962     DOI: 10.1378/chest.112.4.980

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  15 in total

1.  Hepatopulmonary syndromes.

Authors:  M J Krowka
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

Review 2.  The extrahepatic consequences of cirrhosis.

Authors:  Jin Kee Ho; Eric Yoshida
Journal:  MedGenMed       Date:  2006-03-02

Review 3.  Portopulmonary hypertension.

Authors:  Michael Halank; Ralf Ewert; Hans-Juergen Seyfarth; Gert Hoeffken
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

Review 4.  Hepato-cardiac disorders.

Authors:  Yasser Mahrous Fouad; Reem Yehia
Journal:  World J Hepatol       Date:  2014-01-27

Review 5.  Hemodynamic monitoring during liver transplantation: A state of the art review.

Authors:  Mona Rezai Rudnick; Lorenzo De Marchi; Jeffrey S Plotkin
Journal:  World J Hepatol       Date:  2015-06-08

Review 6.  Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects.

Authors:  Søren Møller; Jens H Henriksen; Flemming Bendtsen
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 7.  Pulmonary complications of hepatic diseases.

Authors:  Salim R Surani; Yamely Mendez; Humayun Anjum; Joseph Varon
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

Review 8.  Pulmonary vascular complications of liver disease.

Authors:  Jason S Fritz; Michael B Fallon; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

9.  Intraoperative pulmonary hypertension occurred in an asymptomatic patient with pre-existent liver cirrhotic and portal hypertension.

Authors:  Ling Lu; Feng Zhang; Xiang-Cheng Li; Guo-Qiang Li; Chuan-Yong Zhang; Xue-Hao Wang
Journal:  World J Gastroenterol       Date:  2008-12-21       Impact factor: 5.742

10.  Clinical risk factors for portopulmonary hypertension.

Authors:  Steven M Kawut; Michael J Krowka; James F Trotter; Kari E Roberts; Raymond L Benza; David B Badesch; Darren B Taichman; Evelyn M Horn; Steven Zacks; Neil Kaplowitz; Robert S Brown; Michael B Fallon
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.